RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

David R. Spigel,Luis Paz-Ares,Yuanbin Chen,Maria Jove,Oscar Juan-Vidal,Patricia Rich,Theresa M Hayes,M Vanesa Gutierrez Calderon,Reyes Bernabe Caro,Alejandro Navarro,Afshin Dowlati,Bin Zhang,Yan Moore,Haofei Tiffany Wang,Jaba Kokhreidze,Natalya Nazarenko,Santiago Ponce-Aix,Paul A. Bunn

RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

2020

David R. Spigel
Luis Paz-Ares
Yuanbin Chen
Maria Jove
Oscar Juan-Vidal
Patricia Rich
Theresa M Hayes
M Vanesa Gutierrez Calderon
Reyes Bernabe Caro
Alejandro Navarro
Afshin Dowlati
Bin Zhang
Yan Moore
Haofei Tiffany Wang
Jaba Kokhreidze
Natalya Nazarenko
Santiago Ponce-Aix
Paul A. Bunn

9069Background: Most patients with extensive SCLC develop drug resistance to platinum-based 1L therapy or discontinue for other reasons, and second-line (2L) therapies are limited. RESILIENT (NCT03...

Keywords:

Oncology
non small cell
Liposomal Irinotecan
Internal medicine
open label
Pathology
first line
platinum sensitivity
Platinum
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations